Pharmaceutical

Action Behavior Centers Partners with El Paso Chihuahuas for Autism Awareness Night

EL PASO, TX / ACCESS Newswire / September 13, 2025 / Action Behavior Centers (ABC), a leading provider of evidence-based…

3 months ago

Avicanna Announces Change in CFO

TORONTO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a…

3 months ago

BioNxt Announces Shares for Debt Settlement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS…

3 months ago

Onco-Innovations to Chair Colorectal Cancer Canada Precision Oncology Forum Driving the Future of Cancer Care

VANCOUVER, BC / ACCESS Newswire / September 12, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H)(WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")is pleased to…

3 months ago

MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation

SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% weight loss and…

3 months ago

Zomedica’s Fourth Friday at Four Webinar Returns: Spotlight on TRUVIEW(R) Digital Cytology Microscope – Transforming Veterinary Imaging

Cutting-Edge Digital Microscopy System Featured in Monthly Series Showcasing Innovation in Veterinary Care ANN ARBOR, MI / ACCESS Newswire /…

3 months ago

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves…

3 months ago

InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…

3 months ago

Interim results for the six months ended June 30, 2025

September 12, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa…

3 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing…

3 months ago